Related Experiment Video
Updated: May 17, 2025

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
Published on: December 2, 2016
Heart Conditioning as a Healthy Strategy in Management of Cardiac Enlargement
David Wing-Ching Lee1, William Wing-Ho Lee1, Andrew Ying-Siu Lee1
1Department of Cardiology, Jen-Ai Hospital, Taichung, Taiwan, Republic of China.
Background:
Remote ischemic conditioning (RIC) is widely recognized for its cardioprotective effects in the context of ischemic heart disease. Lately, it has been shown that heart conditioning can be utilized as a healthy strategy in the reversion of disease and aging. In this regard, we examine the impact of RIC on patients with cardiac enlargement.
Methods:
Forty-four patients with cardiac enlargement were prospectively enrolled and randomly assigned into RIC group (n = 22) and control group (n = 22). RIC protocol is 3-min inflation/deflation of the blood pressure cuff applied in the upper arm to create transient arm ischemia. RIC treatment was performed once a day for 1 year. Left atrial and ventricular dimensions and left ventricular ejection fraction (LVEF) were all assessed in two groups.
Results:
RIC was well-tolerated. After 1 year treatment, left atrial and ventricular dimensions were significantly decreased in the RIC group. Moreover, LVEF showed a significant increase, from 46.24% to 56.45% (P < 0.0001).
Conclusion:
The research indicates that a year-long healthy regimen of RIC treatment may effectively reverse cardiac enlargement, thereby endorsing the broader implementation of RIC in the daily routines of these patients.
Related Concept Videos
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Diuretics
Exercise and Cardiac Output
Sustained exercise increases the muscles' oxygen demand, which can be...
Heart Failure Drugs: β-Blockers
Heart Failure Drugs: Inotropic Agents

